Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ines Kovacs"'
Autor:
Brian J. Druker, Lucy C. Crossman, Eric P. Stoffregen, Sandra Otto, Michael W. Deininger, Shannon K. McWeeney, Stephanie G. Willis, Byung Park, Dietger Niederwieser, Shadmehr Demehri, Thoralf Lange, Ines Kovacs
Publikováno v:
Blood. 106:2128-2137
Mutations in the kinase domain (KD) of BCR-ABL are the leading cause of acquired imatinib resistance. In some cases, identical mutations were detected at relapse and in pretherapeutic specimens, consistent with selection of resistant clones in the pr
Autor:
Thoralf Lange, Kathrin Wildenberger, Rayak Stengel, Dietger Niederwieser, Schwabe Scarlett, Karolin Hubert, Anne Koehler, Martin Roskos, Rainer Krahl, Song-Yau Wang, Elisabeth Koehler, Melanie Schneider, Haifa Kathrin Al-Ali, Ines Kovacs, Nadja Jaekel, Karoline Schubert
Publikováno v:
Blood. 124:1860-1860
In retrospective studies, CALR mutation is found to be a favorable prognostic variable in myelofibrosis (MF) compared with JAK2, or MPL mutations. With the availability of the JAK1/JAK2 inhibitor ruxolitinib (RUX) for treatment of MF, it is not yet k
Autor:
Thoralf, Lange, Thomas, Bumm, Sandra, Otto, Haifa-Kathrin, Al-Ali, Ines, Kovacs, Daniela, Krug, Thomas, Köhler, Rainer, Krahl, Dietger, Niederwieser, Michael W N, Deininger
Publikováno v:
Haematologica. 89(1)
Imatinib is the new standard drug treatment for patients with chronic myelogenous leukemia (CML). Quantitative reverse transcription-polymerase chain reaction (qPCR) for detection of BCR-ABL transcripts is frequently used for monitoring patients in a
Autor:
Michael W. Deininger, Dietger Niederwieser, Evelin Hennig, Haifa Kathria Al-Ali, Sabine Leiblein, Ines Kovacs
Publikováno v:
Blood. 100(3)
Most patients with BCR-ABL –positive chronic myeloid leukemia (CML) express e13a2 (b2a2) or e14a2 (b3a2) mRNAs that result from a rearrangement of the major breakpoint cluster region (M- BCR ), while rearrangements of the minor BCR with e1a2 transc
Autor:
Christine Guenther, Thoralf Lange, Ines Kovacs, Song-Yau Wang, Oliver Pelz-Ackermann, Knuth Krohn, Michael Cross, Haifa Kathrin Al-Ali, Michael W. Deininger, Dietger Niederwieser
Publikováno v:
Blood. 108:2191-2191
Mutations of the ABL kinase domain (KD) are the most frequent cause of acquired resistance to imatinib in patients with chronic myeloid leukaemia (CML), most likely due to selection of mutated clones on imatinib treatment. As new Bcr-Abl inhibitors b